Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Jakavi

- PMLiVE

Roche and AZ claim FDA breakthrough status for new drugs

Designation could speed up development for Roche’s ocrelizumab and AZ’s durvalumab 

- PMLiVE

Forging a path in specialty care

Takeda’s Marc Princen on the company’s plans to build a reputation in oncology, gastroenterology and vaccine

- PMLiVE

Incyte abandons solid tumour programme for Jakafi

Drug discontinued after failure to show efficacy in trials

- PMLiVE

Mismanagement of Cancer Drugs Fund “unacceptable”

Influential committee of MPs finds the government still unable to assess CDF's patient benefit

Harnessing complexity

Companion diagnostics in oncology

- PMLiVE

Novartis makes trio of appointments to senior leadership team

Michael Ball, Vas Narasimhan and Andre Wyss take on new roles

Roche Basel Switzerland

Roche shares slip as profits miss expectations

But shows solid sales growth thanks to its oncology portfolio

- PMLiVE

Novartis continues to expand its NHS eyecare partnerships

Will work with Plymouth Hospitals NHS Trust to improve patient outcomes

Novartis day

Novartis shakes up underperforming Alcon unit

Begins revamp of its business, beginning with changes at its eyecare division

- PMLiVE

Dr George Gunn moves from Novartis to join Nuritas

The Irish biotech also adds to its advisory board

- PMLiVE

Novartis’ Entresto launched in UK

Drug was first CHF therapy to show an improvement over ACE inhibitors

EISAI

Eisai’s Lenvima gets FDA priority review for kidney cancer

The oncology treatment could now be approved in the US before the summer

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links